1. Home
  2. PRPO vs VIRX Comparison

PRPO vs VIRX Comparison

Compare PRPO & VIRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRPO
  • VIRX
  • Stock Information
  • Founded
  • PRPO N/A
  • VIRX 2007
  • Country
  • PRPO United States
  • VIRX United States
  • Employees
  • PRPO N/A
  • VIRX N/A
  • Industry
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • VIRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PRPO Industrials
  • VIRX Health Care
  • Exchange
  • PRPO Nasdaq
  • VIRX Nasdaq
  • Market Cap
  • PRPO 9.5M
  • VIRX 7.7M
  • IPO Year
  • PRPO N/A
  • VIRX N/A
  • Fundamental
  • Price
  • PRPO $6.25
  • VIRX $0.15
  • Analyst Decision
  • PRPO
  • VIRX Buy
  • Analyst Count
  • PRPO 0
  • VIRX 4
  • Target Price
  • PRPO N/A
  • VIRX $5.00
  • AVG Volume (30 Days)
  • PRPO 7.5K
  • VIRX 2.7M
  • Earning Date
  • PRPO 11-06-2024
  • VIRX 11-13-2024
  • Dividend Yield
  • PRPO N/A
  • VIRX N/A
  • EPS Growth
  • PRPO N/A
  • VIRX N/A
  • EPS
  • PRPO N/A
  • VIRX N/A
  • Revenue
  • PRPO $17,411,000.00
  • VIRX N/A
  • Revenue This Year
  • PRPO $75.18
  • VIRX N/A
  • Revenue Next Year
  • PRPO N/A
  • VIRX N/A
  • P/E Ratio
  • PRPO N/A
  • VIRX N/A
  • Revenue Growth
  • PRPO 31.31
  • VIRX N/A
  • 52 Week Low
  • PRPO $4.31
  • VIRX $0.15
  • 52 Week High
  • PRPO $8.49
  • VIRX $1.31
  • Technical
  • Relative Strength Index (RSI)
  • PRPO 52.41
  • VIRX 21.60
  • Support Level
  • PRPO $6.14
  • VIRX $0.17
  • Resistance Level
  • PRPO $6.47
  • VIRX $0.21
  • Average True Range (ATR)
  • PRPO 0.19
  • VIRX 0.02
  • MACD
  • PRPO 0.01
  • VIRX -0.00
  • Stochastic Oscillator
  • PRPO 88.00
  • VIRX 0.00

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

About VIRX Viracta Therapeutics Inc.

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

Share on Social Networks: